Moderate Risk of Hepatitis B Virus Reactivation in HBsAg(−)/HBcAb(+) Carriers Receiving Rituximab for Rheumatoid Arthritis

To investigate the incidence and risk factors of hepatitis B virus (HBV) reactivation in HBV surface antigen (HBsAg)(−)/ HBV core antibody (HBcAb)(+) patients who underwent rituximab (RTX) therapy for rheumatoid arthritis (RA). From January 2000 through December 2017, a total of 134 RA patients with...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Sci Rep
Asıl Yazarlar: Kuo, Meng Hsuan, Tseng, Chih-Wei, Lee, Chi-Hui, Tung, Chien-Hsueh, Tseng, Kuo-Chih, Lai, Ning-Sheng
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group UK 2020
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7016116/
https://ncbi.nlm.nih.gov/pubmed/32051458
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-020-59406-4
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller